Gene

NTRK3

neurotrophic receptor tyrosine kinase 3

Explore in graph →CI-GENE-00017361HGNC:8033 ENSG00000140538 NCBI 4916 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (86)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 86 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK3 Fusion1
(oncogenic)	Melanoma	Oncogenic	C	Supports Oncogenicity	2	accepted	EID13047 A 68-year-old woman presented with a painful left facial mass that was excised and pathologically diagnosed as malignant melanoma. Following surgery, she received adjuvant radiotherapy combined with t…

Cohorts

Alteration frequency by cohort (119)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved119 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm

Literature

Linked publications (39)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 39 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
· Lancet Oncol · 2020 · PMID 31838007 · validated civic_curation pubmed
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
· N Engl J Med · 2018 · PMID 29466156 · validated civic_curation pubmed
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
· Lancet Oncol · 2018 · PMID 29606586 · validated civic_curation pubmed
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
· Nat Genet · 1998 · PMID 9462753 · validated civic_curation

NTRK3 Fusion15
(diagnostic)	Infantile FibrosarcomaALIAS	Diagnostic	C	Supports Positive	3	accepted	EID10419 To determine if EML4::NTRK3 fusions were recurrent in tumors types known to harbor ETV6::NTRK3 fusions, the authors screened 63 cases with varying diagnoses (infantile fibrosarcoma, congenital mesobla… (full text at CIViC) PMID 29099503 · Church et al., 2018 · Open in CIViC	civic
〃	Congenital Mesoblastic Nephroma	Diagnostic	C	Supports Positive	3	accepted	EID10420 To determine if EML4::NTRK3 fusions were recurrent in tumors known to harbor ETV6::NTRK3 fusions, the authors screened 63 cases with varying diagnoses (infantile fibrosarcoma, congenital mesoblastic n… (full text at CIViC) PMID 29099503 · Church et al., 2018 · Open in CIViC	civic
〃	Infantile FibrosarcomaALIAS	Diagnostic	C	Supports Positive	3	accepted	EID11517 This case study detailed a 9-month-old male with congenital fibrosarcoma with subsequent metastasis to the lungs. The patient had a history of hemimelia in the same limb as the congenital fibrosarcoma… (full text at CIViC) PMID 27148571 · Tannenbaum-Dvir et al., 2015 · Open in CIViC	civic
(oncogenic)	Cervical Sarcoma	Oncogenic	C	Supports Oncogenicity	1	accepted	EID10483 A 33-year-old Han Chinese woman has been associated with an NTRK fusion cervical sarcoma which was positive for Pan-TRK by immunohistochemistry (IHC) analysis. However, FISH for NTRK1 was negative. Th… (full text at CIViC) PMID 35572973 · Dang et al., 2022 · Open in CIViC	civic
〃	Pancreatic Ductal Adenocarcinoma	Oncogenic	C	Supports Oncogenicity	1	accepted	EID10484 Whole genome sequencing and RNAseq were performed on 400 patients with resected or locally advanced/metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Immunohistochemistry (IHC) analysis was performe… (full text at CIViC) PMID 34583947 · Allen et al., 2023 · Open in CIViC	civic
〃	Colon Adenocarcinoma	Oncogenic	C	Supports Oncogenicity	1	accepted	EID10506 From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. Two cases of… (full text at CIViC) PMID 31375766 · Solomon et al., 2020 · Open in CIViC	civic
〃	GlioblastomaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	1	accepted	EID10507 From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. One case of… (full text at CIViC) PMID 31375766 · Solomon et al., 2020 · Open in CIViC	civic
〃	Poorly Differentiated Thyroid Gland CarcinomaALIAS	Oncogenic	C	Supports Oncogenicity	1	accepted	EID10508 From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. One case of … (full text at CIViC) PMID 31375766 · Solomon et al., 2020 · Open in CIViC	civic
〃	Infantile FibrosarcomaALIAS	Oncogenic	D	Supports Oncogenicity	4	accepted	EID10379 A novel EML4::NTRK3 fusion was identified in a 9-month-old male with a recurrent congenital fibrosarcoma. The in-frame fusion transcript contained exons 1-2 of EML4 fused to exon 14 of NTRK3 which is … (full text at CIViC) PMID 27148571 · Tannenbaum-Dvir et al., 2015 · Open in CIViC	civic
〃	Malignant Colon Neoplasm	Oncogenic	D	Supports Oncogenicity	3	accepted	EID10638 From whole exome sequencing of 278 primary colon tumors with stage I-III, 2.5% carried gene fusion. 1.5% of these were positive for kinase fusions including BRAF, NTRK3 and RET gene fusions. These gen… (full text at CIViC) PMID 28512242 · Kloosterman et al., 2017 · Open in CIViC	civic
Entrectinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID11099 A 45-year-old non-smoking female patient was diagnosed with a stage IV lung adenocarcinoma and magnetic resonance imaging showed multiple brain metastases. Targeted NGS analysis on the pleural biopsy … (full text at CIViC) PMID 36419889 · Lazzari et al., 2022 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID10635 Of 351 primary thyroid carcinoma patients assessed by targeted gene rearrangement next-generation assay, 11 cases (3.1%) had NTRK rearrangement. Only one case of EML4::NTRK3 fusion (e2,e13) with an in… (full text at CIViC) PMID 32457407 · Chu et al., 2020 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID10636 The paper mentions a 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer initially treated with carboplatin/paclitaxel chemotherapy. Upon identification of an … (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
〃	Infantile FibrosarcomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID11859 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
Larotrectinib	High-Grade Glioma, NOS	Predictive	C	Supports Sensitivity Response	3	accepted	EID11100 A 7 month old male had a large cystic mass in his brain surgically resected. Pathological analysis determined the mass to be an infantile high-grade glioma and transcriptome sequencing of the tumor RN… (full text at CIViC) PMID 33403813 · Waters et al., 2021 · Open in CIViC	civic

NTRK3 Fusion15

(diagnostic)

Infantile FibrosarcomaALIAS

Diagnostic

Supports Positive

accepted

EID10419

To determine if EML4::NTRK3 fusions were recurrent in tumors types known to harbor ETV6::NTRK3 fusions, the authors screened 63 cases with varying diagnoses (infantile fibrosarcoma, congenital mesobla… (full text at CIViC)

PMID 29099503 · Church et al., 2018 · Open in CIViC